Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension.

Maria Fleseriu,John Newell-Price,Rosario Pivonello,Akira Shimatsu,Richard J Auchus,Carla Scaroni,Zhanna Belaya,Richard A Feelders,Greisa Vila,Ghislaine Houde,Rama Walia,Miguel Izquierdo,Michael Roughton,Alberto M Pedroncelli,Beverly M K Biller

European journal of endocrinology（2022）

引用 13|浏览14

暂无评分

摘要

Data from this large, multicentre trial show that long-term treatment with osilodrostat sustains cortisol normalisation alongside clinical benefits in most patients with CD and is well tolerated.

查看译文

关键词

osilodrostat,cushing,long-term

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要